CyMedica Orthopedics said today that a study of its E-vive neuromuscular electrical stimulation (NMES) and knee-replacement patient engagement system yielded statistically significant improvements.
The clinical trial results measuring 66 total-knee-replacement patients demonstrate an earlier return to function and increase in quadriceps strength in patients treated with E-vive versus the standard of care, according to researchers at Cleveland Clinic. The patients showed a 12.9% increase in quadriceps strength at the three-week post-operative point (a critical period of time where patients commonly experience a substantial loss of quadriceps strength, 29% loss for the standard of care patients in this trial), and increased timed-up-and-go test times at both the six- and 12-weeks post-surgery.
Scottsdale, Ariz.-based CyMedica announced the results at the American Academy of Orthopaedic Surgeons (AAOS) meeting in Las Vegas.
“The results of this trial demonstrate that pre- and post-surgical muscle strengthening and neuromuscular electrical stimulation therapy was shown to be a significant component for patient rehabilitation to achieve quadriceps strength and an earlier return to activity,” said primary investigator and Cleveland Clinic orthopedic surgeon Carlos Higuera-Rueda, M.D., in a prepared statement from CyMedica. “Combined with the digital health patient engagement features of the device, patients were able to actively participate in more productive rehabilitation following total knee replacement surgery.”
“We are focused on empowering patients throughout their entire journey of knee osteoarthritis, from the early onset of disease to post-surgical rehabilitation,” added CyMedica president and CEO Rob Morocco in a prepared statement. “This is accomplished by providing advanced muscle stimulation solutions that foster patient engagement and improve outcomes.”
